Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Neoadjuvant Chemotherapy With and Without Immunotherapy to CA125 (Oregovomab) Followed by Hypofractionated Stereotactic Radiotherapy & Concurrent HIV Protease Inhibitor Nelfinavir in Locally Advanced Pancreatic Cancer

NCT01959672 is registered in ClinicalTrials.gov with University of Nebraska as lead sponsor.

NCT NCT01959672
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01959672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Neoadjuvant Chemotherapy With and Without Immunotherapy to CA125 (Oregovomab) Followed by Hypofractionated Stereotactic Radiotherapy & Concurrent HIV Protease Inhibitor Nelfinavir in Locally Advanced Pancreatic Cancer
Lead sponsor
University of Nebraska
Phase
Phase 2
Overall status
Completed
Start date
September 6, 2013
Completion date
December 1, 2018
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma, resectable pancreatic carcinoma, stage i pancreatic cancer, stage ia pancreatic cancer, stage ib pancreatic cancer, stage ii pancreatic cancer, stage iia pancreatic cancer, stage iib pancreatic cancer, stage iii pancreatic cancer